Is oral tirzepatide available — and what are your options right now?

Why is there no oral tirzepatide yet, and when might that change?

Tirzepatide works as a dual GIP and GLP-1 receptor agonist, activating two separate gut-hormone pathways involved in appetite regulation and blood-sugar control. Delivering that molecule reliably through the digestive tract is a genuine scientific challenge. Stomach acid and digestive enzymes break down large peptide molecules quickly, which is why most GLP-1 medicines have historically required injection. Eli Lilly, the manufacturer of Mounjaro, is running active trials on an oral tirzepatide formulation, and early phase results have attracted coverage, but phase results are not the same as a finished product sitting in a UK pharmacy. Regulatory review, manufacturing scale-up and MHRA assessment all take time after trial data is published.

If you are curious about the broader timeline for tirzepatide's development, there is more detail there. The honest answer for now is that no one can give a firm date for when oral tirzepatide will be available in the UK, and any source that claims otherwise is speculating. What is certain is that approval (if and when it comes) would require a fresh MHRA evaluation, and supply would then follow through the licensed UK supply chain.

So what oral option does exist for GLP-1 weight management in the UK right now?

The MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer called SNAC) on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The trial that supported approval (OASIS 4, 64 weeks, 307 adults with obesity or overweight alongside at least one weight-related condition) reported an average weight loss of around 13.6% compared with roughly 2.4% on placebo, with higher results among those who stayed fully adherent throughout.

It is worth being clear that semaglutide and tirzepatide are different molecules with different mechanisms. Semaglutide acts on a single GLP-1 pathway; tirzepatide acts on two. They produce different average outcomes in clinical trials, and they suit different people for different clinical reasons. The question of whether Mounjaro will ever come in tablet form is separate from the availability of oral semaglutide today. A prescriber would weigh up which medicine (and which format) fits your circumstances, not just your preference for one route of administration over another.

No refrigeration is needed for the Wegovy tablet, which some people find practical. Storage and administration details are set out in the patient information leaflet, the leaflet, not any summary page, is the definitive reference for how to take it correctly.

Does taking an injection instead of a tablet actually change how well the treatment works?

This is a question our prescribers hear regularly, usually from people who feel uncertain about self-injection. The short answer is that the clinical trial evidence for the Mounjaro injection is substantial. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking tirzepatide 15mg lost an average of around 20 to 21% of their body weight over 72 weeks. That is a larger average reduction than any oral weight-loss medicine currently licensed in the UK produces. The injection format is not the compromise many people assume, it is the version with the most robust evidence behind it.

Injection anxiety is understandable, and it is something worth raising directly with a prescriber rather than ruling out treatment altogether. The Mounjaro KwikPen is a pre-filled, once-weekly device; most people find the technique straightforward after the first use. NICE's appraisal of tirzepatide, TA1026, is based entirely on this injection format. For now, if tirzepatide is clinically suitable for you, the injection is what is available, and the evidence behind it is strong. Information on what private Mounjaro treatment costs is worth reading alongside this, so you have the full picture before deciding how to proceed.

What should you do if you were hoping for an oral tirzepatide option?

Start by being clear on what you are actually looking for. If convenience and avoiding injections are the main drivers, the Wegovy tablet is a licensed oral option, a prescriber can tell you whether it suits your clinical profile. If the specific pharmacology of tirzepatide is the reason (perhaps you have read about the dual-pathway mechanism, or you have a clinical reason your GP or a previous prescriber recommended it), then the Mounjaro injection is the route available to you in the UK today.

You can read more about tirzepatide and how it works to get a clearer sense of the science, or look at our Mounjaro overview if you want the practical detail on the injection itself. Our weight-loss treatment page covers both options side by side. One practical habit: before reading any article about oral tirzepatide, check the publication date and the country it was written for, a lot of content circulates internationally, and US regulatory news, in particular, does not reflect what is licensed or available in the UK.

Every decision about which medicine to take, in what format, starts with a clinical assessment. If you would like a prescriber at our GPhC-registered pharmacy to review your situation, you can check your eligibility and start a free consultation at any point.